Judge tells CVS, Aetna to keep operations separate during antitrust review

A federal judge who has been reviewing the $69 billion merger between CVS Health and Aetna has told the two companies to keep some operations separate during the ongoing antitrust process, The New York Times reported.

The deal, which brings together one of the nation’s largest retail pharmacy chains and pharmacy benefit managers with the nation’s third largest health insurance provider, was approved by regulators earlier this year, including the Department of Justice. However, the deal also must pass through the courts. CVS Health has already closed the deal.

Judge Richard J. Leon, of the United States District Court in the District of Columbia, previously signaled he did not approve of the “rubber stamp” treatment CVS Health’s acquisition of Aetna had been given by the government and regulators and was not satisfied that the deal would not create antitrust issues.

In its preliminary approval of the deal, the DOJ required Aetna to divest its Medicare Part D business, which WellCare Health Plans agreed to acquire in October.

Currently, as the process continues, Judge Leon proposed a government monitor assigned to ensure the entities keep their businesses separate. He also told the companies to “preserve the ability to unwind CVS’ acquisition of Aetna in the event an unwinding is necessary,” The NY Times reported.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.